CV Lattes
Universidade Estadual Paulista (UNESP). Campus de Botucatu. Instituto de Biociências (IBB) (Institutional affiliation from the last research proposal) Birthplace: Brazil
Undergraduated at Biomedical Sciences at Centro Universitário Herminio Ometto, Araras, SP, Brazil (1980), master's at Immunology from Universidade de São Paulo (1988) and Ph.D. at Immunology from Universidade de São Paulo (1994). Pos-doc at University of Pittsburgh, PA, USA. Is an Associate-Professor of Immunology at the Institute of Biosciences at São Paulo State University (UNESP). Reaserch activities are developed with students of Graduating Programs in Pathology (FMB) and Biotechnology (IBB), focusing the role of dendritic cells, natural killer activity, natural products on tumor imunomodulation, and use of nanoparticles as carriers of chemotherapeutic agents. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Interferon alpha (IFN-alpha) is a type I IFN with great therapeutic potential, since it is able to directly fight tumor cells and enhance the maturation of dendritic cells (DCs), the main antigen-presenting cells, required for an effective antitumor response. However, the systemic administration of cytokines can induce severe collateral effects. Therefore, the induction of cytokine secret…
The immunologic tolerance to tumors antigens in cancer patients is one of the main challenges in immunotherapy. Aiming to overcome this tolerance, clinical protocols with dendritic cells (DCs) have been developed, since they are able to induce tumor specific T lymphocyte response. Several approaches have been proposed to improve DCs antigen presentation capacity, including the use of exos…
We have previously observed that ultra-low concentrations of several antineoplastic agents are able to up-regulate the activity of dendritic cells (DC), as well as modify the transcription of a variety of genes of tumor cells, which seems to induce increased immunogenicity on these cells. Among the genes, which transcription was modified by paclitaxel, we cite those associated with the an…
(Only some records are available in English at this moment)
Cancer is featured by an uncontrolled cell proliferation that change the tissue homeostasis and can trigger complications such as pathways blockade, organ compression, and spreading of transformed cells through metastasis. Colorectal cancer is the third main type of cancer worldwide and the most common treatment strategy is chemotherapy, being 5-fluorouracil (5-FU) one of the main drugs u…
Prostate cancer figures as the main type of tumor in male patients and its treatment is done especially by hormonal blockade and prostatectomy, associated or not with chemo and radiotherapy. In cases in which chemotherapy is used, selected drugs for most cases are taxols, which works by interfering with the microtubule function, leading to cell death. Chemotherapy against prostate cancer …
Colorectal cancer (CRC) is the third most prevalent type of cancer worldwide and frequently associated with metastatic complications. Therapeutic strategies used to treat those patients who do not respond to conventional chemotherapy is based on the application of monoclonal antibodies cetuximab or panitumumab, both directed to the epidermal growth factor receptor (EGFR). However, in some…
(Only some records are available in English at this moment)
We have observed that treatment of DC with low concentration of some anti-neoplasic agents, is able to upregulate DC functions and phenotype, as well as increase the susceptibility of tumor cells to specific cytotoxic T lymphocytes. Based on this, we analyzed whether the in vivo combination of low-dose chemotherapy and DC vaccine would be able to increase the immune response to the murine…
| 10 / 4 | Completed research grants |
| 17 / 15 | Completed scholarships in Brazil |
| 1 / 1 | Completed scholarships abroad |
| 28 / 20 | All research grants and scholarships |
| Associated processes | |